You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Prior studies examining SRS for brainstem metastases

From: Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases

Study Treatment modality Patients, n Mean age, y Median tumor volume, mL Median prescribed SRS Dose, Gy Median survival, mo Local tumor control, % Factors associated With shorter survival Complication rate
Huang et al. [8] Gamma Knife 26 56 1.1 16 9 95 Presence of active extracranial disease 27%
Shuto et al. [13] Gamma Knife 25 57.1 2.1 (mean) 13 (mean) 4.9 77 N/A 8%
Fuentes et al. [6] Gamma Knife 28 57.7 2.1 (mean) 19.6 (mean) 12 92 N/A 0%
Yen et al. [14] Gamma Knife 53 57.3 2.8 (mean) 17.6 (mean) 11 87 Presence of extracranial disease 0%
Hussain et al. [9] Gamma Knife 22 60 (median) 0.9 16 8.5 100 N/A 5%
Kased et al. [10] Gamma Knife 42 55 (median) 0.26 16 9 85 Multiple metastases, melanoma primary 10%
Lorenzoni et al. [15] Gamma Knife 25 54 0.6 (mean) 20 (mean) 11.1 95 KPS <80, uncontrolled primary tumor, radiotherapy, SRS < 18 Gy 0%
Koyfman et al. [11] Gamma Knife 43 59 (median) 0.37 15 5.8 85 Lower KPS, larger tumor volume, SIR, GPA 12%
Hatiboglu et al. [7] Linac-based SRT/SRS 60 61 (median) 1 15 4.2 76 Tumor volume ≥4 mL, male sex 20%
Lin et al. [12] Linac-based SRT/SRS 45 59.9 0.4 14 11.6 91 Lower KPS 4%
Present Study Linac-based SRT/SRS 36 61 0.94 17 3 93 Lower GPA, lower prescription dose, fewer fractions 8%